Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LPCN
  • CUSIP: N/A
  • Web: www.lipocine.com
Capitalization:
  • Market Cap: $87.67 million
  • Outstanding Shares: 19,261,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $3.87
  • 52 Week Range: $3.03 - $5.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.46
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.29 per share
  • Price / Book: 3.62
Profitability:
  • EBIDTA: ($16,260,000.00)
  • Return on Equity: -59.98%
  • Return on Assets: -55.98%
Debt:
  • Current Ratio: 11.58%
  • Quick Ratio: 11.58%
Misc:
  • Average Volume: 420,056 shs.
  • Beta: 1.88
  • Short Ratio: 13.2
 

Frequently Asked Questions for Lipocine (NASDAQ:LPCN)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings results on Monday, May, 8th. The company reported ($0.26) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.04. View Lipocine's Earnings History.

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?

3 brokerages have issued 1-year price objectives for Lipocine's stock. Their forecasts range from $10.00 to $38.00. On average, they expect Lipocine's share price to reach $24.33 in the next twelve months. View Analyst Ratings for Lipocine.

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:

  • Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
  • Gregory Bass, Executive Vice President, Chief Commercial Officer
  • Stephen Anthony Hill M.D., Lead Independent Director
  • Jeffrey A. Fink, Director
  • Richard Dana Ono, Director
  • John W. Higuchi, Non-Executive Director

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of Lipocine stock can currently be purchased for approximately $4.67.


MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.33 (421.06% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/20/2017Roth CapitalSet Price TargetBuy$38.00LowView Rating Details
4/26/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
4/24/2017Canaccord GenuitySet Price TargetBuy$10.00HighView Rating Details
(Data available from 7/20/2015 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
Earnings by Quarter for Lipocine (NASDAQ:LPCN)
Earnings History by Quarter for Lipocine (NASDAQ LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20172($0.33)($0.31)($0.32)
Q3 20172($0.28)($0.12)($0.20)
Q4 20172($0.30)($0.15)($0.23)
Q1 20181$0.82$0.82$0.82
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 38.55%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
Source:
DateHeadline
reuters.com logoBRIEF-Lipocine announces submission of special protocol assessment request to FDA on LPCN 1107, an oral alternative for prevention of preterm birth
www.reuters.com - June 27 at 5:23 AM
streetinsider.com logoLipocine (LPCN) Submission of Special Protocol Assessment on LPCN 1107 to FDA
www.streetinsider.com - June 27 at 5:23 AM
nasdaq.com logoLipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth - Nasdaq
www.nasdaq.com - June 27 at 12:23 AM
finance.yahoo.com logoLipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth
finance.yahoo.com - June 27 at 12:22 AM
americanbankingnews.com logoZacks: Brokerages Expect Lipocine Inc. (LPCN) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - June 26 at 4:08 PM
benzinga.com logoLicopine Pops And Drops After LPCN 1021 Meets Primary Endpoint - Benzinga
www.benzinga.com - June 22 at 8:57 AM
americanbankingnews.com logoLipocine Inc. (LPCN) PT Set at $38.00 by Roth Capital
www.americanbankingnews.com - June 21 at 11:22 PM
finance.yahoo.com logoBiotech Industry Showing Signs of a Revival in 2017: Today's Research on Lipocine and Portola Pharmaceuticals
finance.yahoo.com - June 21 at 7:27 PM
benzinga.com logoLipocine Pops And Drops After LPCN 1021 Meets Primary Endpoint
www.benzinga.com - June 20 at 7:18 PM
streetinsider.com logoLipocine (LPCN) Announced Results from Dosing Validation and Dosing Flexibility Studies Evaluating Efficacy and Tolerability of LPCN 1021
www.streetinsider.com - June 20 at 7:18 PM
rttnews.com logoAMGN's Xgeva To Face FDA In Feb, Double Treat For LPCN, SGEN Drops Cascade
www.rttnews.com - June 20 at 3:25 AM
nasdaq.com logoLipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation
www.nasdaq.com - June 19 at 10:24 PM
streetinsider.com logoAfter-Hours Stock Movers 06/19: (LPCN) (ENPH) (TSLA) Higher; (RS) (CMG) (CLVS) Lower (more...)
www.streetinsider.com - June 19 at 10:24 PM
reuters.com logoBRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021
www.reuters.com - June 19 at 10:24 PM
globenewswire.com logoLipocine to Host Conference Call and Webcast to Discuss Top-Line ... - GlobeNewswire (press release)
globenewswire.com - June 19 at 5:22 PM
finance.yahoo.com logoLipocine Validates “No Titration” Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate
finance.yahoo.com - June 19 at 5:22 PM
seekingalpha.com logoThe Future Of Lipocine's Lead Product Candidate, LPCN1021
seekingalpha.com - June 8 at 7:19 PM
americanbankingnews.com logoHead-To-Head Survey: Kindred Biosciences (KIN) and Lipocine (LPCN)
www.americanbankingnews.com - June 8 at 6:50 PM
globenewswire.com logoLipocine to Present at the Jefferies 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 3 at 8:17 AM
finance.yahoo.com logoLipocine to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 2 at 7:44 PM
americanbankingnews.com logo-$0.33 Earnings Per Share Expected for Lipocine Inc (LPCN) This Quarter
www.americanbankingnews.com - May 31 at 12:44 PM
finance.yahoo.com logoLPCN 1021 Readout in June; 1Q:17 R&D Costs Lower
finance.yahoo.com - May 16 at 6:11 PM
americanbankingnews.com logoLipocine Inc Expected to Earn FY2017 Earnings of ($1.17) Per Share (LPCN)
www.americanbankingnews.com - May 15 at 8:43 AM
americanbankingnews.com logoLipocine Inc (LPCN) Expected to Earn Q2 2017 Earnings of ($0.33) Per Share
www.americanbankingnews.com - May 12 at 10:24 AM
businesswire.com logoRobbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - May 11 at 11:52 PM
finance.yahoo.com logoRobbins Arroyo LLP: Lipocine Inc. (LPCN) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - May 9 at 6:05 PM
americanbankingnews.com logoLipocine Inc (LPCN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 12:52 PM
globenewswire.com logoLipocine Announces Financial and Operational Results for the First Quarter 2017 - GlobeNewswire (press release)
globenewswire.com - May 8 at 5:57 PM
finance.yahoo.com logoLipocine Announces Financial and Operational Results for the First Quarter 2017
finance.yahoo.com - May 8 at 10:58 AM
marketbeat.com logoLipocine reports 1Q loss
marketbeat.com - May 8 at 8:15 AM
americanbankingnews.com logoShort Interest in Lipocine Inc (LPCN) Grows By 6.2%
www.americanbankingnews.com - May 5 at 12:24 PM
americanbankingnews.com logo Analysts Anticipate Lipocine Inc (LPCN) to Post -$0.20 Earnings Per Share
www.americanbankingnews.com - May 5 at 12:16 PM
americanbankingnews.com logoLipocine (LPCN) Receives Coverage Optimism Rating of 0.31
www.americanbankingnews.com - May 3 at 2:36 PM
americanbankingnews.com logoLipocine (LPCN) Given News Impact Rating of -0.25
www.americanbankingnews.com - April 30 at 7:49 AM
americanbankingnews.com logoLipocine (LPCN) Given Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 28 at 12:22 AM
americanbankingnews.com logoLipocine's (LPCN) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 26 at 10:12 PM
americanbankingnews.com logoCanaccord Genuity Analysts Give Lipocine Inc (LPCN) a $10.00 Price Target
www.americanbankingnews.com - April 25 at 4:16 PM
americanbankingnews.com logoSomewhat Favorable Press Coverage Somewhat Likely to Affect Lipocine (LPCN) Stock Price
www.americanbankingnews.com - April 24 at 9:34 PM
streetinsider.com logoLipocine (LPCN) Says Enrollment in LPCN 1021 Fixed Dose Trials Has Been Completed
www.streetinsider.com - April 24 at 4:58 PM
finance.yahoo.com logoLipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials
finance.yahoo.com - April 24 at 4:58 PM
americanbankingnews.com logoLipocine (LPCN) Receiving Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 18 at 10:00 AM
americanbankingnews.com logoLipocine (LPCN) Earns Daily Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 15 at 12:11 PM
americanbankingnews.com logoLipocine Inc (LPCN) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 14 at 1:16 PM
globenewswire.com logoLipocine to Present at 16th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 28 at 10:57 PM
globenewswire.com logoLipocine to Present at 27th Annual Oppenheimer Conference - GlobeNewswire (press release)
globenewswire.com - March 15 at 11:37 PM
finance.yahoo.com logoLipocine to Present at 27th Annual Oppenheimer Conference
finance.yahoo.com - March 14 at 11:21 AM
streetinsider.com logoH.C. Wainwright Remains bullish on Lipocine (LPCN) Following 4Q
www.streetinsider.com - March 13 at 6:05 PM
us.rd.yahoo.com logoLPCN: Conserving Cash to Fund Underway DV and DF Studies
us.rd.yahoo.com - March 13 at 6:05 PM
americanbankingnews.com logoLipocine Inc (LPCN) Given a $25.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 13 at 4:28 PM
streetinsider.com logoH.C. Wainwright Remains bullish on Lipocine (LPCN) Following 4Q - StreetInsider.com
www.streetinsider.com - March 13 at 10:32 AM

Social

Chart

Lipocine (LPCN) Chart for Thursday, July, 20, 2017

This page was last updated on 7/20/2017 by MarketBeat.com Staff